Nomogram Predicting Renal Insufficiency after Nephroureterectomy for Upper Tract Urothelial Carcinoma in the Chinese Population: Exclusion of Ineligible Candidates for Adjuvant Chemotherapy
Table 2
Predictive factors for identifying patients ineligible to receive reduced dose of cisplatin-based adjuvant chemotherapy#.
Postoperative eGFR (mL/min/1.73 m2)
Univariate analysis
Multivariate analysis
All
≥45
<45
Chi-square
value
OR
95% CI
value
All, number (%)
485 (100)
375 (77.3)
110 (22.3)
Gender, number (%)
0.685
0.236
Male
224 (46.2)
177 (47.2)
47 (42.7)
Female
261 (53.8)
198 (52.8)
63 (57.3)
Age∧, number (%)
6.773
0.006*
0.999
0.996–1.003
0.922
<70
260 (53.6)
213 (56.8)
47 (42.7)
≥70
225 (46.4)
162 (43.2)
63 (57.3)
Preoperative eGFR (mL/min/1.73 m2)∧, number (%)
34.365
<0.001*
0.991
0.989–0.993
<0.001*
<60
353 (72.8)
297 (79.2)
56 (50.9)
≥60
132 (27.2)
78 (20.8)
54 (49.1)
Previous or concomitant BT, number (%)
0.004
0.546
No
418 (86.2)
323 (86.1)
95 (86.4)
Yes
67 (13.8)
52 (13.9)
15 (13.6)
Side, number (%)
0.645
0.244
Left
235 (48.5)
178 (47.5)
57 (51.8)
Right
250 (51.5)
197 (52.5)
53 (48.2)
Location, number (%)
9.325
0.002*
1.164
1.074–1.262
<0.001*
Ureter
234 (48.2)
195 (52.0)
39 (35.5)
Pelvis
251 (51.8)
180 (48.0)
71 (64.5)
Hydronephrosis, number (%)
12.523
<0.001*
0.881
0.813–0.956
0.002*
No
228 (47.0)
160 (42.7)
68 (61.8)
Yes
257 (53.0)
215 (57.3)
42 (38.2)
Multifocality, number (%)
0.853
0.215
No
398 (82.1)
311 (82.9)
87 (79.1)
Yes
87 (17.9)
64 (17.1)
23 (20.9)
DM, number (%)
0.091
0.444
No
401 (92.7)
309 (82.4)
92 (83.6)
Yes
84 (17.3)
66 (17.6)
18 (16.4)
Hypertension, number (%)
0.877
0.204
No
292 (60.2)
230 (61.3)
62 (56.4)
Yes
193 (39.8)
145 (38.7)
48 (43.6)
Smoking, number (%)
0.276
0.344
No
392 (80.8)
305 (81.3)
87 (79.1)
Yes
93 (19.2)
70 (18.7)
23 (20.9)
Tumor size (cm)∧, number (%)
16.163
<0.001*
0.969
0.955–0.983
0.001*
<3
267 (55.1)
188 (50.1)
79 (71.8)
≥3
218 (44.9)
187 (49.9)
31 (28.2)
Architecture, number (%)
13.392
<0.001*
Papillary
362 (74.6)
266 (70.9)
96 (87.3)
Sessile
117 (24.1)
105 (28.0)
12 (10.9)
Stage, number (%)
19.838
<0.001*
Ta/T1/T2
330 (68.0)
236 (62.9)
94 (85.5)
T3/T4
155 (32.0)
139 (37.1)
16 (14.5)
Grade, number (%)
9.525
0.001*
G1-2
282 (58.1)
204 (54.4)
78 (70.9)
G3
203 (41.9)
171 (45.6)
32 (29.1)
Tumor necrosis, number (%)
3.385
0.043*
No
436 (89.9)
332 (88.5)
104 (94.5)
Yes
49 (10.1)
43 (11.5)
6 (5.5)
CIS, number (%)
0.579
0.350
Absent
471 (97.1)
363 (96.8)
108 (98.2)
Present
14 (2.9)
12 (3.2)
2 (1.8)
Statistically significant.
#Only patients with preoperative eGFR ≥ 45 mL/min/1.73 m2 were included. ∧Initially calculated as binary variables in univariate analysis and used as linear variable in multivariate analysis. OR: odds ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate; BT: bladder tumor; DM: diabetes mellitus; CIS: carcinoma in situ.
